{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:37:07Z","timestamp":1793144227190,"version":"4.5.0"},"reference-count":99,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>There has been a renewed effort globally in the study of older Hodgkin lymphoma (HL) patients, generating a multitude of new data. For prognostication, advancing age, comorbidities, altered functional status, Hispanic ethnicity, and lack of dose intensity (especially without anthracycline) portend inferior survival. Geriatric assessments (GA), including activities of daily living (ADL) and comorbidities, should be objectively measured in all patients. In addition, proactive multidisciplinary medical management is recommended (eg, geriatrics, cardiology, primary care), and pre-phase therapy should be considered for most patients. Treatment for fit older HL patients should be given with curative intent, including anthracyclines, and bleomycin should be minimized (or avoided). Brentuximab vedotin given sequentially before and after doxorubicin, vinblastine, dacarbazine (AVD) chemotherapy for untreated patients is tolerable and effective, and frontline checkpoint inhibitor\/AVD platforms are rapidly emerging. Therapy for patients who are unfit or frail, whether due to comorbidities and\/or ADL loss, is less clear and should be individualized with consideration of attenuated anthracycline-based therapy versus lower-intensity regimens with inclusion of brentuximab vedotin +\/- checkpoint inhibitors. For all patients, there should be clinical vigilance with close monitoring for treatment-related toxicities, including neurotoxicity, cardiopulmonary, and infectious complications. Finally, active surveillance for \u201cpostacute\u201d complications 1 to 10 years post therapy, especially cardiac disease, is needed for cured patients. Altogether, therapy for older HL patients should include anthracycline-based therapy in most cases, and novel targeted agents should continue to be integrated into treatment paradigms, with more research needed on how best to utilize GAs for treatment decisions.<\/jats:p>","DOI":"10.1182\/hematology.2023000449","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:12:16Z","timestamp":1702048336000},"page":"483-499","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Hodgkin lymphoma treatment for older persons in the modern era"],"prefix":"10.1182","volume":"2023","author":[{"given":"Andrew M.","family":"Evens","sequence":"first","affiliation":[{"name":"1 Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"McKenna","sequence":"additional","affiliation":[{"name":"1 Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Kyoung","family":"Ryu Tiger","sequence":"additional","affiliation":[{"name":"1 Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenica N.","family":"Upshaw","sequence":"additional","affiliation":[{"name":"2 Division of Cardiology, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"1","key":"2023120815072455800_hem2023000449C1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ejh.13090","article-title":"Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-a population-based study from Sweden","volume":"101","author":"Bjorkholm","year":"2018","journal-title":"Eur J Haematol"},{"issue":"4","key":"2023120815072455800_hem2023000449C2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oxfordjournals.annonc.a057939","article-title":"Treatment outcome in Hodgkin's disease in patients above the age of 60: a population-based study","volume":"2","author":"Enblad","year":"1991","journal-title":"Ann Oncol"},{"issue":"4","key":"2023120815072455800_hem2023000449C3","first-page":"438","article-title":"Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren","year":"2003","journal-title":"Haematologica"},{"issue":"25","key":"2023120815072455800_hem2023000449C4","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2023120815072455800_hem2023000449C5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","article-title":"Northern Region Lymphoma Group. Hodgkin's disease in the elderly: a population-based study","volume":"119","author":"Stark","year":"2002","journal-title":"Br J Haematol"},{"issue":"22","key":"2023120815072455800_hem2023000449C6","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023120815072455800_hem2023000449C7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/1097-0142(19920815)70:4<830::AID-CNCR2820700418>3.0.CO;2-X","article-title":"Hodgkin disease in the elderly. A registry-based analysis","volume":"70","author":"Erdkamp","year":"1992","journal-title":"Cancer"},{"issue":"4","key":"2023120815072455800_hem2023000449C8","first-page":"1087","article-title":"Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen","volume":"20","author":"Weekes","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7-8","key":"2023120815072455800_hem2023000449C9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/028418602321028283","article-title":"Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy","volume":"41","author":"Enblad","year":"2002","journal-title":"Acta Oncol"},{"issue":"12","key":"2023120815072455800_hem2023000449C10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2012.47.3058","article-title":"How can outcomes be improved for older patients with Hodgkin lymphoma?","volume":"31","author":"Evens","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2023120815072455800_hem2023000449C11","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/1097-0142(19930301)71:5<1857::AID-CNCR2820710524>3.0.CO;2-B","article-title":"Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B","volume":"71","author":"Mir","year":"1993","journal-title":"Cancer"},{"issue":"3","key":"2023120815072455800_hem2023000449C12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0959-8049(99)00267-1","article-title":"Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries","volume":"36","author":"Roy","year":"2000","journal-title":"Eur J Cancer"},{"issue":"1","key":"2023120815072455800_hem2023000449C13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"2023120815072455800_hem2023000449C14","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood-2007-10-115493","article-title":"Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"issue":"22","key":"2023120815072455800_hem2023000449C15","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1182\/bloodadvances.2022008258","article-title":"The outcome of older adults with classic Hodgkin lymphoma in British Columbia","volume":"6","author":"Cheng","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2023120815072455800_hem2023000449C16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjh.18564","article-title":"A comprehensive SEER registry analysis of elderly patients with classical Hodgkin lymphoma based on treatment era and race","volume":"200","author":"Shah","year":"2023","journal-title":"Br J Haematol"},{"issue":"3","key":"2023120815072455800_hem2023000449C17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jha2.202","article-title":"Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged &gt;60 years","volume":"2","author":"Wahlin","year":"2021","journal-title":"EJHaem"},{"issue":"21","key":"2023120815072455800_hem2023000449C18","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"30","key":"2023120815072455800_hem2023000449C19","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023120815072455800_hem2023000449C20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2023120815072455800_hem2023000449C21","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.22.02473","article-title":"The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: development and validation of a clinical prediction model from the HoLISTIC Consortium","volume":"41","author":"Rodday","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2023120815072455800_hem2023000449C22","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","article-title":"Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis","volume":"23","author":"Evens","year":"2012","journal-title":"Ann Oncol"},{"issue":"22","key":"2023120815072455800_hem2023000449C23","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023120815072455800_hem2023000449C24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/annonc\/mdh012","article-title":"VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study","volume":"15","author":"Levis","year":"2004","journal-title":"Ann Oncol"},{"issue":"7","key":"2023120815072455800_hem2023000449C25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002770050521","article-title":"Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996","volume":"78","author":"van Spronsen","year":"1999","journal-title":"Ann Hematol"},{"issue":"7","key":"2023120815072455800_hem2023000449C26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ejca.2005.01.010","article-title":"Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry","volume":"41","author":"van Spronsen","year":"2005","journal-title":"Eur J Cancer"},{"issue":"2","key":"2023120815072455800_hem2023000449C27","first-page":"1","article-title":"Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group","volume":"60","author":"Wrobel","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2023120815072455800_hem2023000449C28","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2023120815072455800_hem2023000449C29","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2023120815072455800_hem2023000449C30","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jgo.2021.07.003","article-title":"Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin lymphoma who receive dose-intense chemotherapy","volume":"12","author":"Kumar","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"11","key":"2023120815072455800_hem2023000449C31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"2023120815072455800_hem2023000449C32","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/bloodadvances.2021004777","article-title":"A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL","volume":"5","author":"Isaksen","year":"2021","journal-title":"Blood Adv"},{"issue":"19","key":"2023120815072455800_hem2023000449C33","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"issue":"20","key":"2023120815072455800_hem2023000449C34","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood-2017-05-736975","article-title":"Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma","volume":"130","author":"Lin","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2023120815072455800_hem2023000449C35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hon.2830","article-title":"Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland","volume":"39","author":"Moccia","year":"2021","journal-title":"Hematol Oncol"},{"issue":"9","key":"2023120815072455800_hem2023000449C36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ncponc1186","article-title":"Treatment of Hodgkin lymphoma: the past, present, and future","volume":"5","author":"Evens","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"10","key":"2023120815072455800_hem2023000449C37","doi-asserted-by":"crossref","first-page":"e2128373","DOI":"10.1001\/jamanetworkopen.2021.28373","article-title":"Association of treatment intensity with survival in older patients with Hodgkin lymphoma","volume":"4","author":"Rodday","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2023120815072455800_hem2023000449C38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.16525","article-title":"First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study","volume":"190","author":"Rodday","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"2023120815072455800_hem2023000449C39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2023.01.014","article-title":"Characteristics and outcomes of older patients with classical Hodgkin lymphoma: an Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study","volume":"23","author":"Goh","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl","key":"2023120815072455800_hem2023000449C40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/01.HS9.0000890896.83681.49","article-title":"AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients","volume":"6","author":"\u00d6vergaard","year":"2022","journal-title":"HemaSphere"},{"issue":"24","key":"2023120815072455800_hem2023000449C41","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"issue":"19","key":"2023120815072455800_hem2023000449C42","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","article-title":"Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023120815072455800_hem2023000449C43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/annonc\/mdl379","article-title":"Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group","volume":"18","author":"Klimm","year":"2007","journal-title":"Ann Oncol"},{"issue":"12","key":"2023120815072455800_hem2023000449C44","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"issue":"18","key":"2023120815072455800_hem2023000449C45","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023120815072455800_hem2023000449C46","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/10428190601126610","article-title":"Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma","volume":"48","author":"Kolstad","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2023120815072455800_hem2023000449C47","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0360-3016(02)04596-0","article-title":"Hodgkin's disease in elderly patients (&gt; or\u200a=\u200a60): clinical outcome and treatment strategies","volume":"56","author":"Kim","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"2023120815072455800_hem2023000449C48","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/annonc\/mdl094","article-title":"A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients","volume":"17","author":"Landgren","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"2023120815072455800_hem2023000449C49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdi023","article-title":"A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)","volume":"16","author":"Ballova","year":"2005","journal-title":"Ann Oncol"},{"issue":"1","key":"2023120815072455800_hem2023000449C50","first-page":"46","article-title":"Probability of cure in elderly Hodgkin\u2019s disease patients","volume":"79","author":"Levis","year":"1994","journal-title":"Haematologica"},{"issue":"5","key":"2023120815072455800_hem2023000449C51","first-page":"450","article-title":"Results of a low aggressivity chemotherapy regimen (CVP\/CEB) in elderly Hodgkin\u2019s disease patients","volume":"81","author":"Levis","year":"1996","journal-title":"Haematologica"},{"issue":"7","key":"2023120815072455800_hem2023000449C52","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/10428190290033332","article-title":"Treatment of elderly Hodgkin's lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study","volume":"43","author":"Macpherson","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2023120815072455800_hem2023000449C53","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase II study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"B\u00f6ll","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2023120815072455800_hem2023000449C54","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2009-11-253211","article-title":"Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"116","author":"Halbsguth","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2023120815072455800_hem2023000449C55","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-101-4-447","article-title":"BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen: results of the Eastern Cooperative Oncology Group Study","volume":"101","author":"Bakemeier","year":"1984","journal-title":"Ann Intern Med"},{"issue":"25","key":"2023120815072455800_hem2023000449C56","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2023120815072455800_hem2023000449C57","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1080\/10428194.2019.1608529","article-title":"Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (&gt;\/\u200a=\u200a70years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)","volume":"60","author":"Salvi","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2023120815072455800_hem2023000449C58","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2021-152346","article-title":"Final analysis of a prospective multicenter phase II trial of the Lymphoma Study Association (LYSA) using prednisone, vinblastine, doxorubicin and bendamustine (PVAB) regimen in first line therapy for patients over 60 years with advanced-stage classical Hodgkin lymphoma","volume":"138","author":"Ghesquieres","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815072455800_hem2023000449C59","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2018-99-112178","article-title":"Older patients (pts) with previously untreated classical Hodgkin lymphoma (cHL): a detailed analysis from the phase 3 ECHELON-1 study","volume":"132","author":"Evens","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023120815072455800_hem2023000449C60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bjh.15741","article-title":"Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial","volume":"185","author":"B\u00f6ll","year":"2019","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"2023120815072455800_hem2023000449C61","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2018-99-119363","article-title":"B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)","author":"Boell","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2023120815072455800_hem2023000449C62","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjh.18947","article-title":"\u201cACOPP\u201d chemotherapy for older and less fit patients with Hodgkin lymphoma-a multicentre, retrospective study","volume":"202","author":"Wilson","year":"2023","journal-title":"Br J Haematol"},{"issue":"10","key":"2023120815072455800_hem2023000449C63","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"S2","key":"2023120815072455800_hem2023000449C64","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/hon.3163_107","article-title":"Phase 2 trial of nivolumab plus adriamycin vinblastin, dacarbazine (N-AVD) as frontline therapy in older adults with Hodgkin lymphoma [abstract]","volume":"41","author":"Torka","year":"2023","journal-title":"Hematologic Oncology"},{"issue":"26","key":"2023120815072455800_hem2023000449C65","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2023120815072455800_hem2023000449C66","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023120815072455800_hem2023000449C67","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.17073","article-title":"Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)","volume":"193","author":"Gibb","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"2023120815072455800_hem2023000449C68","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2023120815072455800_hem2023000449C69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood-2021-147863","article-title":"Nivolumab first-line therapy for elderly, frail Hodgkin lymphoma patients: NIVINIHO, a LYSA phase II study","volume":"138","author":"Lazarovici","year":"2021","journal-title":"Blood"},{"issue":"S2","key":"2023120815072455800_hem2023000449C70","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hon.3163_106","article-title":"Pembrolizumab as first therapy for Hodgkin lymphoma is deliverable in older or ABVD-ineligible patients, allows subsequent therapy, and gives adequate survival","volume":"41","author":"Dickinson","year":"2023","journal-title":"Hematol Oncol"},{"issue":"1","key":"2023120815072455800_hem2023000449C71","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/hematology.2019000028","article-title":"Management of older Hodgkin lymphoma patients","volume":"2019","author":"Evens","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2023120815072455800_hem2023000449C72","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/bmt.2010.294","article-title":"High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma","volume":"46","author":"Puig","year":"2011","journal-title":"Bone Marrow Transpl"},{"issue":"35","key":"2023120815072455800_hem2023000449C73","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","article-title":"Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023120815072455800_hem2023000449C74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0609.1989.tb00268.x","article-title":"Hodgkin's disease and age","volume":"43","author":"Specht","year":"1989","journal-title":"Eur J Haematol"},{"issue":"5","key":"2023120815072455800_hem2023000449C75","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"2023120815072455800_hem2023000449C76","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"2023120815072455800_hem2023000449C77","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pupt.2005.01.007","article-title":"Bleomycin lung toxicity: who are the patients with increased risk?","volume":"18","author":"Azambuja","year":"2005","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"2023120815072455800_hem2023000449C78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jgo.2019.09.009","article-title":"Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin lymphoma","volume":"11","author":"Thomas","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"34","key":"2023120815072455800_hem2023000449C79","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","article-title":"Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors","volume":"35","author":"Salz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2023120815072455800_hem2023000449C80","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.HS9.0000890900.69504.65","article-title":"The effect of heart failure on management and outcomes of older patients with Hodgkin lymphoma","volume":"6","author":"Upshaw","year":"2022","journal-title":"HemaSphere"},{"issue":"5","key":"2023120815072455800_hem2023000449C81","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.cardfail.2022.02.009","article-title":"2022 American College of Cardiology\/American Heart Association\/Heart Failure Society of America Guideline for the Management of Heart Failure: executive summary","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J Card Fail"},{"issue":"9","key":"2023120815072455800_hem2023000449C82","first-page":"CD014638","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"de Baat","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2023120815072455800_hem2023000449C83","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","article-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023120815072455800_hem2023000449C84","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline- based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"issue":"8","key":"2023120815072455800_hem2023000449C85","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1200\/JCO.2015.60.8851","article-title":"Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children\u2019s Oncology Group Randomized Trial Pediatric Oncology Group 9404","volume":"34","author":"Asselin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2023120815072455800_hem2023000449C86","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001813-200606000-00014","article-title":"Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis","volume":"17","author":"Batist","year":"2006","journal-title":"Anti-Cancer Drugs"},{"issue":"3","key":"2023120815072455800_hem2023000449C87","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"2023120815072455800_hem2023000449C88","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D","article-title":"Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation","volume":"65","author":"Shapira","year":"1990","journal-title":"Cancer"},{"issue":"5","key":"2023120815072455800_hem2023000449C89","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bjh.18348","article-title":"Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: preliminary results of a single-centre phase II study","volume":"198","author":"Picardi","year":"2022","journal-title":"Br J Haematol"},{"issue":"10","key":"2023120815072455800_hem2023000449C90","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"2023120815072455800_hem2023000449C91","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for Anthracycline- Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"2023120815072455800_hem2023000449C92","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"issue":"11","key":"2023120815072455800_hem2023000449C93","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2023120815072455800_hem2023000449C94","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JOP.2016.018770","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"13","author":"Armenian","year":"2017","journal-title":"J Oncol Pract"},{"key":"2023120815072455800_hem2023000449C95","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Survivorship. 2023. https:\/\/www.nccn.org\/guidelines\/recently-published-guidelines. Accessed July3, 2023."},{"issue":"35","key":"2023120815072455800_hem2023000449C96","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1200\/JCO.20.00264","article-title":"Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000-2016","volume":"38","author":"Dores","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023120815072455800_hem2023000449C97","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1186\/s12885-021-08683-x","article-title":"Causes of death and effect of non-cancer-specific death on rates of overall survival in adult classic Hodgkin lymphoma: a populated-based competing risk analysis","volume":"21","author":"Gao","year":"2021","journal-title":"BMC Cancer"},{"issue":"5","key":"2023120815072455800_hem2023000449C98","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/j.cardfail.2022.03.285","article-title":"Prevalent heart failure and cardioprotective medication use in older individuals with lymphoma: a SEER- Medicare analysis","volume":"28","author":"Upshaw","year":"2022","journal-title":"J Card Fail"},{"issue":"10","key":"2023120815072455800_hem2023000449C99","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/483\/2175841\/483evens.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/483\/2175841\/483evens.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:12:53Z","timestamp":1702048373000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/483\/506388\/Hodgkin-lymphoma-treatment-for-older-persons-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000449","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}